References in periodicals archive ?
MTX, NSAIDS, DMARDs, mAbs, anti-TNF alpha agents, and IL-1 blockers make up the "alphabet" of different drugs in RA therapy.
* Drug Category: Disease-Modifying Antirheumatic Drugs (DMARDs) for Rheumatoid Arthritis
This open-label, randomized, controlled trial is the first and only H2H study that utilizes on-label dosing for both Taltz and Humira and includes concomitant conventional DMARDs. At 24 weeks, patients treated with Taltz met the primary endpoint by demonstrating superiority in improving the signs and symptoms of active PsA compared to Humira as measured by the proportion of patients simultaneously achieving at least a 50% reduction in disease activity, as defined by the American College of Rheumatology, or ACR50, as well as complete skin clearance as measured by the Psoriasis area and severity index.
Additionally, MTX has been shown to have better long-term retention rates than other disease-modifying anti-rheumatic drugs (DMARDs) (9).
Those not taking disease-modifying antirheumatic medications (DMARDs), however, had a normal immune response, which suggests that it's the immunomodulating medications, not the disease itself, that are affecting antibody levels, Roger Hesselstrand, MD, of Lund (Sweden) University and his colleagues reported online in Rheumatology.
The products are intended for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs).
Objective: To determine the disease severity in patients with Rheumatoid Arthritis (RA), at baseline and the impact of treatment on disease activity (DA) after six months of disease modifying anti-rheumatic drugs (DMARDs) therapy.
A new study confirms that early treatment of rheumatoid arthritis (RA) with low-dose steroids, combined with disease-modifying antirheumatic drugs (DMARDs), taken at the lowest possible dose and for the shortest period of time, is safe and effective.
Safety concerns associated with biologic and nonbiologic DMARDs include increased CV risk, liver and hematologic toxicity, renal impairment, infection, and bleeding.
They include disease-modifying anti-rheumatic drugs (DMARDs) that alter the course of the disease and prevent or decrease joint damage.
Treatment choices consist of a mono- or combination therapy with non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biological agents for ERA, which are primarily based on adult studies and axial or peripheral involvement.
Currently, disease-modifying antirheumatic drugs (DMARDs)*2 including Methotrexate (MTX) and biologies, are used to treat rheumatoid arthritis.